Enhanced chemoluminescence

Manufactured by Advansta

Sourced in United States

Enhanced chemoluminescence is a lab equipment product that utilizes chemiluminescent reactions to produce light. It is designed to detect and quantify specific molecules or proteins in biological samples. The core function of this product is to generate and measure the light emitted from chemiluminescent reactions, which can be used to analyze and study various biological and biochemical processes.

Automatically generated - may contain errors

Lab products found in correlation

Mre11 12d7 ab214, by Abcam (2 mentions) β actin 1 19 sc 1616, by Santa Cruz Biotechnology (2 mentions) Phospho histone h2a x ser139, by Cell Signaling Technology (1 mentions) Trizol reagent, by Thermo Fisher Scientific (1 mentions) Histone h3, by Abcam (1 mentions) Phospho atm ser 1981, by Abcam (1 mentions) Ab1791, by Abcam (1 mentions) Ab81292, by Abcam (1 mentions) Sc 8035, by Santa Cruz Biotechnology (1 mentions) Mre11, by Abcam (1 mentions) Phospho p53 ser15, by Cell Signaling Technology (1 mentions) Caspase 3 9662, by Cell Signaling Technology (1 mentions) Viia 7 real time pcr system, by Thermo Fisher Scientific (1 mentions) 384 well microfluidic card taqman gene expression assay, by Thermo Fisher Scientific (1 mentions)

4 protocols using enhanced chemoluminescence

Protein Extraction and Analysis Protocol

Cited 2 times

Check if the same lab product or an alternative is used in the 5 most similar protocols

mRNA was extracted using TRIzol reagent (Invitrogen Corporation) and quantitative reverse transcription-PCR was performed as described.^{54 (link)} Primer sequences are given as Supplementary materials. Total protein extraction and western blot protocol have been previously described.^{54 (link)} Chromatin fractionation was performed as described.^{57 (link)} Primary antibodies were as follows: MYCN (B8.4.B), SC53993, p53 (DO-1) SC-126, CHK1 (G4), SC8408, Tubulin, (TU-02), SC-8035, and β-Actin (I-19) SC-1616 Santa Cruz Biotechnology; phospho-CHK1 (S317), DR1025, Calbiochem (San Diego, CA, USA); RAD50 (13B3/2C6), ab89, Mre11 (12D7) ab214, ZIC1 ab72694, Histone H3, ab1791, phospho-ATM (Ser 1981), ab81292, Rad50, ab499, and Mre11, ab6511, Abcam (Cambridge, UK); NBS1 (1C3) GTX70222, Gene Tex (Irvine, CA, USA); p53 (1C12), #2524, phospho-p53 (Ser 15), #9284, and phospho- histone H2AX (ser 139), #2577, Cell Signaling Technology (Danvers, MA, USA); PARP p85 fragment, #G7341, Promega Corporation; RPA32, A300-244 A, phospho-RPA32 S4/S8, A300-245 A, Bethyl Laboratories (Montgomery, TX, USA); Nbs1 (Y112), NB110-57272, Novus Biologicals; Immunoreactive bands were visualized by enhanced chemoluminescence (Advansta Inc., Menlo Park, CA, USA).

Petroni M., Sardina F., Heil C., Sahún-Roncero M., Colicchia V., Veschi V., Albini S., Fruci D., Ricci B., Soriani A., Di Marcotullio L., Screpanti I., Gulino A, & Giannini G. (2015). The MRN complex is transcriptionally regulated by MYCN during neural cell proliferation to control replication stress. Cell Death and Differentiation, 23(2), 197-206.

+ Open protocol

+ Expand

Protein Extraction and Western Blot

Cited 1 time

Check if the same lab product or an alternative is used in the 5 most similar protocols

Total protein extraction and western blot protocols have been previously described^{56 (link)}. Immunoreactive bands were visualized by enhanced chemoluminescence (Advansta Inc., Menlo Park, CA, USA). Antibodies were as follows: MRE11 (12D7) ab214 (Abcam, Cambridge, UK); PARP 85 fragment #G7341 (Promega Corporation, Medison, WI, USA); Caspase-3 #9662, phospho-histone H2AX (ser 139) #2577 and phospho-p53 (Ser 15) #9284 (Cell Signaling Technology, Danvers, MA), USA; p53 (DO-1) #SC-126 and β-actin (I–19) #SC-1616 (Santa Cruz Biotechnology, INC, Dallas, TX, USA).

Petroni M., Sardina F., Infante P., Bartolazzi A., Locatelli E., Fabretti F., Di Giulio S., Capalbo C., Cardinali B., Coppa A., Tessitore A., Colicchia V., Sahùn Roncero M., Belardinilli F., Di Marcotullio L., Soddu S., Comes Franchini M., Petricci E., Gulino A, & Giannini G. (2018). MRE11 inhibition highlights a replication stress-dependent vulnerability of MYCN-driven tumors. Cell Death & Disease, 9(9), 895.

+ Open protocol

+ Expand

Protein Extraction and Immunoblotting

Check if the same lab product or an alternative is used in the 5 most similar protocols

Total protein extracts were obtained and separated as described [52 (link)–54 (link)]. Primary antibodies and peroxidase-conjugated secondary antibodies are listed in the supplemental information. Immunoreactive bands were visualized by enhanced chemoluminescence (Advansta Inc., Menlo Park, CA, USA).

Di Giulio S., Colicchia V., Pastorino F., Pedretti F., Fabretti F., Nicolis di Robilant V., Ramponi V., Scafetta G., Moretti M., Licursi V., Belardinilli F., Peruzzi G., Infante P., Goffredo B.M., Coppa A., Canettieri G., Bartolazzi A., Ponzoni M., Giannini G, & Petroni M. (2021). A combination of PARP and CHK1 inhibitors efficiently antagonizes MYCN-driven tumors. Oncogene, 40(43), 6143-6152.

+ Open protocol

+ Expand

Quantitative Analysis of mRNA and Protein

Cited 1 time

Check if the same lab product or an alternative is used in the 5 most similar protocols

mRNA and protein extraction were performed as previously described [38 (link)]. Quantitative PCR (qPCR) was performed on a ViiA 7 real‐time PCR system (Thermo Fisher Scientific) as previously described [39 (link)] or using a custom 384‐Well Microfluidic Card TaqMan Gene Expression Assay (Thermo Fisher Scientific). The list of qPCR assays is given in Supplementary Information. At least three biological replicates were analysed for each experimental condition. All values were normalised on the expression of at least two reference genes. mRNA quantification was quantified through the ΔΔCt method.
Total protein extraction and Western blot protocols were performed as described [38 (link), 40 (link)]. Immunoreactive bands were visualised by enhanced chemoluminescence (Advansta Inc., Menlo Park, CA, USA). The list of antibodies is given in Supplementary Table 5.

Petroni M., Fabretti F., Di Giulio S., Nicolis di Robilant V., La Monica V., Moretti M., Belardinilli F., Bufalieri F., Coppa A., Paci P., Corsi A., De Smaele E., Coni S., Canettieri G., Di Marcotullio L., Wang Z, & Giannini G. (2022). A gene dosage‐dependent effect unveils NBS1 as both a haploinsufficient tumour suppressor and an essential gene for SHH‐medulloblastoma. Neuropathology and Applied Neurobiology, 48(6), e12837.

+ Open protocol

+ Expand

About PubCompare

Our mission is to provide scientists with the largest repository of trustworthy protocols and intelligent analytical tools, thereby offering them extensive information to design robust protocols aimed at minimizing the risk of failures.

We believe that the most crucial aspect is to grant scientists access to a wide range of reliable sources and new useful tools that surpass human capabilities.

However, we trust in allowing scientists to determine how to construct their own protocols based on this information, as they are the experts in their field.

Ready to get started?

Revolutionizing how scientists
search and build protocols!